Versant funds report lower Tempest Therapeutics (TPST) ownership levels

Rhea-AI Filing Summary

Tempest Therapeutics, Inc. received an updated ownership report from several Versant-managed funds on Schedule 13D/A Amendment No. 7. The amendment reflects dilution of their stakes after the company sold additional common shares.

Versant Venture Capital VI, L.P. now reports beneficial ownership of 16,149 shares, or 0.1% of Tempest’s common stock. Versant Vantage II, L.P. reports 162,972 shares, or 1.1%. Versant Venture Capital IV, L.P. reports 90,084 shares, or 0.6%, and Versant Side Fund IV, L.P. reports 567 shares. Versant Ventures IV, LLC reports 90,651 shares, or 0.6%. Percentages are based on 14,344,034 shares outstanding as of March 25, 2026, per Tempest’s Form 10-K.

Key Figures

Versant VI beneficial ownership: 16,149 shares (0.1%) Versant Vantage II LP ownership: 162,972 shares (1.1%) Versant IV ownership: 90,084 shares (0.6%) +3 more

6 metrics

Versant VI beneficial ownership 16,149 shares (0.1%) Tempest common stock as of March 25, 2026

Versant Vantage II LP ownership 162,972 shares (1.1%) Tempest common stock as of March 25, 2026

Versant IV ownership 90,084 shares (0.6%) Tempest common stock as of March 25, 2026

Versant Side Fund IV ownership 567 shares (0.0%) Tempest common stock as of March 25, 2026

Versant Ventures IV LLC ownership 90,651 shares (0.6%) Tempest common stock as of March 25, 2026

Shares outstanding 14,344,034 shares Tempest common stock outstanding as of March 25, 2026 (Form 10-K)

Key Terms

beneficial ownership, dispositive power, Schedule 13D, dilution, +1 more

5 terms

beneficial ownership financial

"may be deemed to have beneficial ownership over such securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power financial

"voting, investment and dispositive power over the shares held"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13D regulatory

"previously filed a statement on Schedule 13G to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

dilution financial

"due to dilution caused by the Issuer's sales of additional shares"

Dilution occurs when a company issues additional shares, increasing the total number of shares outstanding. This can reduce the ownership percentage and voting power of existing shareholders, similar to slicing a pie into more pieces—each piece becomes smaller. For investors, dilution can mean a reduced stake in the company and potentially lower earnings per share, affecting the value of their investment.

Reporting Persons regulatory

"collectively, the "Reporting Persons""

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

Tempest Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

87978U108

(CUSIP Number)

Max Eisenberg
One Sansome Street, Suite 1650
San Francisco, CA, 94104
415-801-8100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/30/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Venture Capital VI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 16,149.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 16,149.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

16,149.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by Versant Venture Capital IV, L.P. ("Versant IV"), Versant Side Fund IV, L.P. ("Side Fund IV"), Versant Ventures IV, LLC ("LLC IV"), Versant Venture Capital VI, L.P. ("Versant VI"), Versant Ventures VI GP, L.P. ("GP VI"), Versant Ventures VI GP-GP, LLC ("LLC VI"), Versant Vantage II, L.P. ("Vantage II LP"), Versant Vantage II GP, L.P. ("Vantage II GP"), Versant Vantage II GP-GP, LLC ("Vantage II LLC" and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the "Reporting Persons"). LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D (as defined in Item 1 below)) outstanding as of March 25, 2026, as set forth in the Issuer's yearly report on Form 10-K for the year ended December 31, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on March 30, 2026 (the "Form 10-K").

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Ventures VI GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 16,149.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 16,149.00

11

Aggregate amount beneficially owned by each reporting person

16,149.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Ventures VI GP-GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 16,149.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 16,149.00

11

Aggregate amount beneficially owned by each reporting person

16,149.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Vantage II, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 162,972.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 162,972.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

162,972.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Vantage II GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 162,972.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 162,972.00

11

Aggregate amount beneficially owned by each reporting person

162,972.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Vantage II GP-GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 162,972.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 162,972.00

11

Aggregate amount beneficially owned by each reporting person

162,972.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Venture Capital IV, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 90,084.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 90,084.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

90,084.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.6 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant IV. LLC IV is the general partner of Versant IV and has voting, investment and dispositive power over the shares held by Versant IV and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Side Fund IV, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 567.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 567.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

567.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Side Fund IV. LLC IV is the general partner of Side Fund IV and has voting, investment and dispositive power over the shares held by Side Fund IV and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

CUSIP Number(s): 87978U108

1

Name of reporting person

Versant Ventures IV, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 90,651.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 90,651.00

11

Aggregate amount beneficially owned by each reporting person

90,651.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.6 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page includes (i) 90,084 shares held by Versant IV; and (ii) 567 shares held by Side Fund IV. LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 14,344,034 shares of Common Stock outstanding as of March 25, 2026, as set forth in the Form 10-K.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: Tempest Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 2000 Sierra Point Parkway, Suite 400, Brisbane, CALIFORNIA , 94005.
Item 1 Comment: This Amendment No. 7 (this "Amendment") amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on May 9, 2022, as amended by Amendment No. 1 filed with the Commission on November 9, 2023, Amendment No. 2 filed with the Commission on February 8, 2024, Amendment No. 3 filed with the Commission on May 13, 2024, Amendment No. 4 filed with the Commission on August 12, 2024, Amendment No. 5 filed with the Commission on February 11, 2025, and Amendment No. 6 filed with the Commission on August 13, 2025 ("Amendment No. 6") (collectively, the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. This Amendment is being filed to update the aggregate percentage of Common Stock owned by the Reporting Persons due to dilution caused by the Issuer's sales of additional shares of its Common Stock from time to time since the date of the filing of Amendment No. 6. Such transactions resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in Amendment No. 6.
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
(b)	See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
(e)	March 30, 2026.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Versant Venture Capital VI, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Date:	04/02/2026

Versant Ventures VI GP, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P.
Date:	04/02/2026

Versant Ventures VI GP-GP, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer
Date:	04/02/2026

Versant Vantage II, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Vantage II GP-GP, LLC, the general partner of Versant Vantage II GP, L.P., the GP of Versant Vantage II, L.P.
Date:	04/02/2026

Versant Vantage II GP, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer of Versant Vantage II GP-GP, LLC, the general partner of Versant Vantage II GP, L.P.
Date:	04/02/2026

Versant Vantage II GP-GP, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer
Date:	04/02/2026

Versant Venture Capital IV, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer of Versant Ventures IV, LLC, the general partner of Versant Venture Capital IV, L.P.
Date:	04/02/2026

Versant Side Fund IV, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer of Versant Ventures IV, LLC, the general partner of Versant Side Fund IV, L.P.
Date:	04/02/2026

Versant Ventures IV, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/Chief Operating Officer
Date:	04/02/2026

FAQ

What does the latest Schedule 13D/A filing say about Versant’s stake in Tempest Therapeutics (TPST)?

The filing shows Versant-managed funds now hold small minority stakes in Tempest Therapeutics. Versant Venture Capital VI, L.P. reports 16,149 shares (0.1%), Versant Vantage II, L.P. reports 162,972 shares (1.1%), and other Versant entities together report additional fractions of the common stock.

Why did Versant update its Schedule 13D on Tempest Therapeutics (TPST)?

The amendment updates Versant’s ownership percentage after Tempest issued additional shares. The document states the change reflects dilution from the issuer’s sales of common stock since Amendment No. 6, which reduced the aggregate percentage ownership reported by the Versant-affiliated reporting persons by over one percent.

How many Tempest Therapeutics (TPST) shares are outstanding in this Schedule 13D/A?

The ownership percentages are based on 14,344,034 Tempest common shares outstanding. That figure is taken from Tempest’s Form 10-K for the year ended December 31, 2025, which reported 14,344,034 shares of common stock outstanding as of March 25, 2026.

Which Versant entities hold Tempest Therapeutics (TPST) shares according to this amendment?

Several Versant funds and general partners are listed as reporting persons. These include Versant Venture Capital VI, L.P., Versant Vantage II, L.P., Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., and Versant Ventures IV, LLC, along with their related general partner and GP-GP entities.

Does the Schedule 13D/A describe a coordinated group position in Tempest Therapeutics (TPST)?

The reporting persons expressly disclaim status as a “group.” Although multiple Versant-related entities report beneficial ownership and shared or sole voting and dispositive power, the amendment states they expressly disclaim being a group for Schedule 13D purposes under the securities laws.

How is beneficial ownership of Tempest Therapeutics (TPST) stock allocated among Versant entities?

Shares are held by specific funds, with GP entities deemed to share control. For example, Versant VI directly holds 16,149 shares, while its general partner entities may be deemed to share voting and investment power. Similar structures apply to Versant Vantage II, Versant IV, and Side Fund IV.